2021 Refresher - Gastrointestinal

Lower GI

This session will outline the current standard of care options and new data regarding the treatment of lower gastrointestinal malignancies. First we will discuss the treatment of locally advanced rectal cancer focusing on the role of radiation in the multidisciplinary treatment of this disease. Data from randomized trials presented at ASCO 2020 will be highlighted as well the ASTRO clinical practice guidelines for rectal cancer published in January/February 2021. Special topics of clinical interest will be discussed including selective omission of radiation therapy for low risk patients and non-operative management for patients with a complete clinical response after radiation. Finally, we will discuss the role of chemoradiation in the definitive treatment of anal squamous cell carcinoma as well as the current cooperative group trials in this space.

Upper GI

Data is rapidly emerging in the treatment of locally advanced GI cancers.  Issues regarding optimal radiation dose, use of radiation, use of immunotherapy and sequence have all been evaluated in phase III trial recently and have direct relevance to practice now. In this educational session we will evaluate: Esophageal cancer- role of adjuvant immunotherapy, dose escalation in inoperable cancers  Pancreatic cancer- the role of preoperative radiation in borderline resectable pancreatic cancer Rectal cancer- Total neoadjuvant therapy and non-operative management.

Target Audience

The activity is designed to meet the interests of radiation oncologists, medical oncologists and radiation oncology residents.

Learning Objectives

    Lower GI

    Upon completion of this live activity, attendees should be able to: 

    • Implement appropriate radiation options for a patient with locally advanced rectal adenocarcinoma.
    • Discuss controversial topics such as omission of surgery and omission of radiation for patients with locally advanced rectal adenocarcinoma.
    • Outline standard of care chemoradiation for patients with anal squamous cell carcinoma.

    Upper GI

    Upon completion of this live activity, attendees should be able to: 

    • Recognize appropriate radiation dose recommendations for non-operative management of esophageal cancer.
    • Discuss the data and limitations of studies evaluating neoadjuvant radiation for borderline resectable pancreatic cancer.
    • Discuss the data supporting total neoadjuvant therapy for rectal cancer, and its relevance to non-operative management.
    Course summary
    Available credit: 
    • 1.50 Certificate of Attendance
      This activity was designated for 1.50 AMA PRA Category 1 Credit™.
    • 1.50 SA-CME

      The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

      The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.

    Course opens: 
    03/19/2021
    Course expires: 
    04/20/2021
    Cost:
    $0.00
    Rating: 
    0

    Emma Holliday, MD is employed by University of Texas Anderson Center and has financial interest from Merck.

    Theodore Hong, MD is employed by Massachusetts General Hospital and has no financial interests.

    The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.

    All relevant relationships have been mitigated.

     

    Disclosure link: 
    Faculty Disclosure

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

    ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

    Available Credit

    • 1.50 Certificate of Attendance
      This activity was designated for 1.50 AMA PRA Category 1 Credit™.
    • 1.50 SA-CME

      The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

      The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.

    Price

    Cost:
    $0.00
    Please login or register to take this course.

    Policies: 
        • No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
        • No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
        • ASTRO staff cannot make modifications to your submitted materials.
     

    Required Hardware/software

    One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.